Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

591
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
591
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Association Areas of the Cortex01:21

Association Areas of the Cortex

9.7K
Association areas are regions of the cerebral cortex that do not have a specific sensory or motor function. Instead, they integrate and interpret information from various sources to enable higher cognitive processes such as memory, learning, and decision-making. Some key association areas include the following:
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...
9.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Deprescribing in cognitively vulnerable older people: adaptation into French language of STOPPCog criteria].

Geriatrie et psychologie neuropsychiatrie du vieillissement·2026
Same author

Subjective cognitive decline: Memory complaints, cognitive awareness, and metacognition.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2024
Same author

Clinical versus biomarker-based diagnosis of neurocognitive disorders - Authors' reply.

The Lancet. Neurology·2024
Same author

Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline.

Brain : a journal of neurology·2024
Same author

Sharing brain imaging data in the Open Science era: how and why?

The Lancet. Digital health·2024
Same author

Amyloid-PET imaging predicts functional decline in clinically normal individuals.

Alzheimer's research & therapy·2024

Related Experiment Video

Updated: Feb 19, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.3K

[Frontotemporal dementia : an update].

Cecilia Ferrer Soler1, Vagia Giatrakou2, Sonia Papa1

  • 1Service de gériatrie, Département de médecine interne, de réhabilitation et de gériatrie, HUG, 1211 Genève 14.

Revue Medicale Suisse
|November 10, 2017
PubMed
Summary

Frontotemporal dementia is often misdiagnosed as psychiatric issues and presents a diagnostic challenge due to its varied forms. Recent research into genetic mutations offers hope for future targeted therapies for this complex neurological condition.

More Related Videos

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

977
Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue FACS-RTT to Determine the Cellular Origin of Radioactive Signal
12:04

Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue FACS-RTT to Determine the Cellular Origin of Radioactive Signal

Published on: September 10, 2021

2.8K

Related Experiment Videos

Last Updated: Feb 19, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.3K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

977
Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue FACS-RTT to Determine the Cellular Origin of Radioactive Signal
12:04

Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue FACS-RTT to Determine the Cellular Origin of Radioactive Signal

Published on: September 10, 2021

2.8K

Area of Science:

  • Neurology
  • Genetics
  • Psychiatry

Background:

  • Frontotemporal dementia (FTD) is a group of progressive neurodegenerative disorders.
  • FTD is frequently underdiagnosed and initially misattributed to psychiatric conditions.
  • The heterogeneity of FTD presents significant diagnostic and clinical challenges.

Purpose of the Study:

  • To highlight the diagnostic complexities of Frontotemporal dementia.
  • To underscore the importance of a multidisciplinary approach in patient care.
  • To discuss the impact of recent genetic research on understanding FTD.

Main Methods:

  • Review of clinical presentations and diagnostic challenges in FTD.
  • Analysis of the heterogeneity across different FTD subtypes.
  • Examination of recent advancements in FTD genetic research.

Main Results:

  • FTD is characterized by diverse clinical manifestations and diagnostic uncertainty.
  • Current treatments primarily manage symptoms, lacking disease-modifying options.
  • Genetic research has significantly improved the understanding of FTD pathology.

Conclusions:

  • Multidisciplinary care is essential for patients with Frontotemporal dementia and their families.
  • Advances in understanding genetic mutations pave the way for potential targeted therapies.
  • Further research is crucial for improved diagnosis and treatment of FTD.